PD-L1 antibody

Phase 3Small molecule

WWest China Hospital

PD-L1 antibody is one of 48 small molecule programs targeting PD-L1 Antibody. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PD-L1 AntibodyRecruiting

Cervical CancerRecruiting

PD-L1 AntibodyPhase 2

Recruiting

Cervical CancerPhase 3

Recruiting

Competition

Competitive Landscape

115 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

45 2

Avastin

Roche

Phase 3

22 3

Paraplatin

AAvyxa

Phase 3

36 4

Keytruda

Merck & Co.

Phase 3

12 5

Trodelvy

Gilead

Phase 3

5 6

Lenvima

Eisai

Phase 3

3 7

Taxotere

AAvyxa

Phase 3

6 8

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

2 9

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

2 10

Rescue

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

PD-L1 Antibody

NCT06742424

Q2 2033

Phase 2/3Recruiting

Cervical Cancer

NCT07472153

Clinical

Trials by Indication[1]

PD-L1 Antibody1 trial

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

Recruiting·WWest China Hospital·Phase 2·NCT06742424·36 enrolled

Lymphoma1 trial

Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

Unknown status·HHitGen Inc.·Phase 1·NCT04977167·96 enrolled

Cervical Cancer1 trial

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Recruiting·NN.N. Alexandrov National Cancer Centre·Phase 2/3·NCT07472153·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PD-L1 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-L1 antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-L1 antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWest China Hospital

PD-L1 antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2033

Trials by Indication[1]

PD-L1 Antibody1 trial

Lymphoma1 trial

Cervical Cancer1 trial

References

Drug Info

Quick Facts

Related News